Former head of FDA concerned about faster drug approvals

The just-departed commissioner of the U.S. Food and Drug Administration (FDA) has concerns about plans to speed up drug approvals and dramatically reduce regulations at the agency, as advocated recently by President Donald Trump.

Robert Califf, who stepped down last month, shared his thoughts about keeping Americans safe — and making sure drugs actually work — after about a year overseeing the federal agency. Here are his takeaways:

1. Faster drug approvals, being advocated by Trump and others, don’t necessarily mean less expensive drugs.

“What I’m concerned about is that when people hear ‘faster approval,’ you get an image of the FDA sitting on this application and, you know, twiddling thumbs,” Califf says. “That’s not what happens.”

Califf says the slow part of getting a drug into patients’ hands happens well before the drugmaker submits an application to the FDA. It can take decades to discover, tweak and test a new drug molecule, and that development process is what needs a boost.

“The real action [happens] before the application gets submitted, and that can be a time frame from years to decades as people try to figure out what will work and what will not,” Califf says.

Although faster drug development could bring development costs down, Califf says, “There’s not a direct relationship between the cost of development and the price of drugs or devices.”

2. A law passed in December should streamline drug approvals — in a positive way.

The 21^st Century Cures Act, a bipartisan bill signed by President Barack Obama late last year, is a “very well-rounded piece of legislation that will speed up product development.”

To begin with, it encourages the FDA to consider pieces of information in its approval process in addition to traditional clinical trials, including “real world evidence” and biomarkers. Biomarkers are used in studies in place of outcomes that are more difficult to measure. For example, tumor shrinkage is sometimes a biomarker for surviving cancer.

“Using real-world evidence in clinical trials is one that I’m particularly excited about as a way to get better answers at a lower cost and faster at the same time,” Califf says.

3. But Califf has concerns about maintaining drug safety standards and ensuring thorough clinical trials.

“The concept of safety is much more complex than most people think about until they look into it deeply,” Califf says. “All drugs have risk. None of them are absolutely safe. And the actual safety risks are only revealed through clinical trials with the same quality and number of patients involved as it takes to look at efficacy.”

About 92 percent of drugs that get into clinical trials don’t make it to market because they fail to show any benefit or, worse, they have unexpected toxicity, he says.

“Declaring a drug is safe after very little information is treacherous,” Califf says.

Califf recently wrote for the Journal of the American Medical Association on the FDA’s balancing act of protecting the public and encouraging innovation. And the FDA released a paper last month documenting examples of a promising drug, vaccine or device that each did well in a Phase 2 clinical trial but “bombed out” in Phase 3, Califf says. Drugs typically go through three ‘phases’ of studies called clinical trials before gaining FDA approval. With each new phase, researchers test drugs or other products on more people and on more measures of safety and effectiveness.

“It’s 22 examples of why it’s a big mistake to think that you can judge the balance of risk and benefit from a small amount of data,” Califf says.

4. Faster, better drugs can’t be approved if the FDA is understaffed, Califf says.

Califf calls a potential FDA hiring freeze “unfortunate” and says new staff are needed to meet the faster approval timelines and to give advice to those developing drugs so “bad mistakes” aren’t made.

The FDA has been steadily hiring staff to keep up with the growing industry it oversees. But hundreds of openings are still left to be filled.

Califf says the drug industry’s most valued interaction with the FDA is “during the process of [drug] development,” which begins before a drug application is submitted for approval. FDA staff can provide timely feedback and advice that can help a company choose the right studies needed for approval and, effectively, speed up drug development.

“A hiring freeze at this time when we are just revving up with 21^st Century Cures is unfortunate. I hope that the dust will settle soon and the FDA can get back to its hiring,” Califf says.

5. The FDA is using big data to track the safety of drugs already on the market — and it plans to do that a lot more.

The FDA has an established adverse event database, but after pain reliever Vioxx was pulled from the market in 2004, the agency began working on a system called Sentinel.

The initiative uses claims data to look at drug safety. It has 180 million individual electronic records and tracks every dispensed prescription, hospitalization and serious outcomes, Califf says. In addition, Sentinel is now being opened up to industry and academia.

“It’s used every day by the FDA,” Califf says, adding that the system is “getting better and better.”

Kaiser Health News’ coverage of prescription drug development, costs and pricing is supported in part by the Laura and John Arnold Foundation.

This story originally appeared on Kaiser Health News. It has been slightly modified to reflect Spectrum’s style.